Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases.

Immunotherapy - 1 Apr 2021

Nunno Vincenzo Di, Nuvola Giacomo, Mosca Mirta, Maggio Ilaria, Gatto Lidia, Tosoni Alicia, Lodi Raffaele, Franceschi Enrico, Brandes Alba Ariela

Abstract excerpt

Brain metastases (BMs) represent a negative prognostic factor for patients with solid malignancies. BMs are generally approached with loco-regional treatments and the blood-brain barrier limits the efficacy of some systemic drugs. The aim of this review is to summarize current knowledge about the role of immune checkpoint inhibitors for the management of brain metastases in patients with solid malignancies. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Renal Cell

Share to Combined Modality Therapy

Share to Immune Checkpoint Inhibitors

Share to Kidney Neoplasms

Share to Melanoma

Share to Radiotherapy

Source

Identifiers

PMID: 33472433
DOI: 10.2217/imt-2020-0208

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases.PMID 33472433Read ↗

Systemic therapies for melanoma brain metastases: which drug for whom and when?Semantic proximity Read ↗

Melanoma brain metastasis: overview of current management and emerging targeted therapies.Semantic proximity Read ↗

Immune checkpoint inhibitors as first-line treatment for brain metastases in stage IV NSCLC patients without driver mutations.Semantic proximity Read ↗

Management of brain metastasized non-small cell lung cancer (NSCLC) - From local treatment to new systemic therapies.Semantic proximity Read ↗

Targeted Therapy in Brain Metastases: Ready for Primetime?Semantic proximity Read ↗

Unraveling the Enigma of Melanoma Brain Metastasis: New Horizons in Mechanisms, Diagnosis, and TherapySemantic proximity Read ↗

Multidisciplinary approach to brain metastasis from melanoma: the emerging role of systemic therapies.Semantic proximity Read ↗

BRAF-MEK inhibition in melanoma brain metastases: a new hope.Semantic proximity Read ↗

The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases.Semantic proximity Read ↗

Immunotherapy: an emerging modality to checkmate brain metastasisSemantic proximity Read ↗

BRAF/MEK Inhibition as a Bridge to Immunotherapy for Symptomatic BRAF V600 Melanoma Brain Metastases: A Case Series.Semantic proximity Read ↗

Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.